The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

PubWeight™: 0.95‹?› | Rank: Top 15%

🔗 View Article (PMID 27070704)

Published in Cancer Cell on April 11, 2016

Authors

Elizabeth C Townsend1, Mark A Murakami1, Alexandra Christodoulou1, Amanda L Christie1, Johannes Köster2, Tiffany A DeSouza1, Elizabeth A Morgan3, Scott P Kallgren4, Huiyun Liu1, Shuo-Chieh Wu1, Olivia Plana1, Joan Montero1, Kristen E Stevenson5, Prakash Rao6, Raga Vadhi6, Michael Andreeff7, Philippe Armand1, Karen K Ballen8, Patrizia Barzaghi-Rinaudo9, Sarah Cahill1, Rachael A Clark10, Vesselina G Cooke9, Matthew S Davids1, Daniel J DeAngelo1, David M Dorfman3, Hilary Eaton11, Benjamin L Ebert12, Julia Etchin13, Brant Firestone9, David C Fisher1, Arnold S Freedman1, Ilene A Galinsky1, Hui Gao9, Jacqueline S Garcia1, Francine Garnache-Ottou14, Timothy A Graubert8, Alejandro Gutierrez15, Ensar Halilovic9, Marian H Harris16, Zachary T Herbert17, Steven M Horwitz18, Giorgio Inghirami19, Andrew M Intlekofer18, Moriko Ito9, Shai Izraeli20, Eric D Jacobsen1, Caron A Jacobson1, Sébastien Jeay9, Irmela Jeremias21, Michelle A Kelliher22, Raphael Koch1, Marina Konopleva7, Nadja Kopp1, Steven M Kornblau7, Andrew L Kung23, Thomas S Kupper10, Nicole R LeBoeuf10, Ann S LaCasce1, Emma Lees9, Loretta S Li13, A Thomas Look13, Masato Murakami9, Markus Muschen24, Donna Neuberg5, Samuel Y Ng1, Oreofe O Odejide1, Stuart H Orkin13, Rachel R Paquette25, Andrew E Place13, Justine E Roderick22, Jeremy A Ryan1, Stephen E Sallan13, Brent Shoji26, Lewis B Silverman13, Robert J Soiffer1, David P Steensma1, Kimberly Stegmaier13, Richard M Stone1, Jerome Tamburini27, Aaron R Thorner25, Paul van Hummelen25, Martha Wadleigh1, Marion Wiesmann9, Andrew P Weng28, Jens U Wuerthner9, David A Williams23, Bruce M Wollison25, Andrew A Lane1, Anthony Letai1, Monica M Bertagnolli24, Jerome Ritz1, Myles Brown2, Henry Long2, Jon C Aster3, Margaret A Shipp1, James D Griffin1, David M Weinstock29

Author Affiliations

1: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA.
2: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA; Center for Functional Cancer Epigenomics, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
3: Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
4: Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02115, USA.
5: Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
6: Center for Functional Cancer Epigenomics, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
7: Leukemia Division, MD Anderson Cancer Center, Houston, TX 77030, USA.
8: Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
9: Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA; Novartis Institutes for Biomedical Research, 4056 Basel, Switzerland.
10: Department of Dermatology, Brigham and Women's Hospital, Boston, MA 02115, USA.
11: Office of Research and Technology Ventures, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
12: Department of Hematology, Brigham and Women's Hospital, Boston, MA 02115, USA.
13: Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
14: EFS Bourgogne Franche Comté, INSERM UMR1098, 25020 Besançon, France.
15: Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02215, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
16: Department of Pathology, Boston Children's Hospital, Boston, MA 02215, USA.
17: Molecular Biology Core Facility, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
18: Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
19: Department of Pathology, Weill Cornell Medical College, New York, NY 10065, USA.
20: Functional Genomics and Leukemia Research, Sheba Medical Center, Tel Hashomer and Tel Aviv University, Ramat Gan, 52621, Israel.
21: Department of Gene Vectors, Helmholtz Zentrum München, German Research Center for Environmental Health, Marchioninistraße 25, 81377 Munich, Germany; Department of Pediatrics, Dr. von Hauner Children's Hospital, Ludwig Maximilians University, Lindwurmstraße 4, 80337 Munich, Germany.
22: Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA 01655, USA.
23: Department of Pediatrics, Columbia University Medical Center, New York, NY 10032, USA.
24: Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
25: Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
26: Department of Surgery, Brigham and Women's Hospital, Boston, MA 02115, USA.
27: Université Paris Descartes, Faculté de Médecine Sorbonne Paris Cité, 75005 Paris, France.
28: Department of Pathology, British Columbia Cancer Research Center, Vancouver V5Z 1H8, Canada.
29: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA. Electronic address: dweinstock@partners.org.

Articles cited by this

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78

Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov (2004) 15.57

limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res (2015) 14.81

Capturing heterogeneity in gene expression studies by surrogate variable analysis. PLoS Genet (2007) 12.08

Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol (2008) 11.05

Acute lymphoblastic leukemia. N Engl J Med (2004) 7.83

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov (2011) 3.86

Snakemake--a scalable bioinformatics workflow engine. Bioinformatics (2012) 3.80

A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res (2009) 3.38

Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood (2004) 3.13

Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov (2014) 2.98

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat Med (2015) 2.95

BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood (2012) 2.91

Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood (2008) 2.66

A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res (2013) 2.63

Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res (2008) 2.56

The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res (2013) 2.27

Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell (2014) 2.15

A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood (2013) 2.14

Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res (2012) 2.04

Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A (2011) 1.97

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med (2012) 1.65

Lost in translation: animal models and clinical trials in cancer treatment. Am J Transl Res (2014) 1.63

Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res (2012) 1.58

The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. Nature (2014) 1.57

Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat Biotechnol (2015) 1.47

Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell (2015) 1.46

A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097. Elife (2015) 1.28

Examining the utility of patient-derived xenograft mouse models. Nat Rev Cancer (2015) 1.21

Translational research: 4 ways to fix the clinical trial. Nature (2011) 1.20

Phenotypic instability of Saos-2 cells in long-term culture. Biochem Biophys Res Commun (2005) 1.18

The littlest patient. Science (2014) 1.18

Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia. Clin Cancer Res (2015) 1.14

Role of Microenvironment in Resistance to Therapy in AML. Curr Hematol Malig Rep (2015) 0.92

Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097. Mol Cancer Ther (2015) 0.86

Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. J Natl Compr Canc Netw (2015) 0.81

Recent advances of p53-MDM2 small molecule inhibitors (2011-present). Curr Med Chem (2015) 0.77

Articles by these authors

KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol (2013) 1.68

Sequence-Intrinsic Mechanisms that Target AID Mutational Outcomes on Antibody Genes. Cell (2015) 1.63

Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBPα expression. Sci Transl Med (2016) 1.38

Mediator kinase inhibition further activates super-enhancer-associated genes in AML. Nature (2015) 1.27

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. Cancer Cell (2015) 1.10

Anaplastic lymphoma kinase-positive large B-cell lymphoma: an underrecognized aggressive lymphoma. Adv Hematol (2012) 0.91

Immunohistochemical detection of hairy cell leukemia in paraffin sections using a highly effective CD103 rabbit monoclonal antibody. Am J Clin Pathol (2013) 0.86

ABCB5 Identifies Immunoregulatory Dermal Cells. Cell Rep (2015) 0.82

Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia. Cancer Cell (2016) 0.77

Spt5 Plays Vital Roles in the Control of Sense and Antisense Transcription Elongation. Mol Cell (2017) 0.75

Mdm2 Phosphorylation Regulates Its Stability and Has Contrasting Effects on Oncogene and Radiation-Induced Tumorigenesis. Cell Rep (2016) 0.75

Multiplex CRISPR/Cas9-Based Genome Editing in Human Hematopoietic Stem Cells Models Clonal Hematopoiesis and Myeloid Neoplasia. Cell Stem Cell (2017) 0.75